Business Wire

THALES

6.6.2022 14:02:12 CEST | Business Wire | Press release

Share
Thales and Palo Alto Networks Deliver New Security Integrations to Help Organisations Implement Zero Trust Security

As organisations continue their digital transformation journeys and move more of their workloads, networking, and security frameworks to the cloud, there is increasing pressure for businesses to rollout sufficiently robust security solutions to safeguard their networks. A long-standing collaboration between the two global cybersecurity leaders, Thales and Palo Alto Networks, will help support this widespread cloud migration, allowing organisations to implement Zero Trust security systems at scale. Through three technology integrations, businesses will gain access to Internal Resources within a robust, highly resilient security architecture.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005079/en/

This news comes at a time where cloud transformation at enterprise-level is occurring at pace to support an increasingly hybrid working world. In line with this shift, it is critical that businesses secure distributed IT environments that no longer have a defined physical security perimeter. The combination of identity aware contextual access controls and multi-factor authentication systems will enable secure cloud transformation whilst supporting remote workforces, allowing employees to safely access any resource, from anywhere, and on any device.

Three key integrations

The integrations will minimise the threat of data breaches from identity compromise by implementing strong, adaptive authentication at the network edge and by ensuring automated remediation workflows in the event of an untrusted access event.

By integrating Thales’ SafeNet Trusted Access across Palo Alto Networks Prisma® Access, GlobalProtect, ML-Powered Next Generation Firewalls, and Cortex® XSOAR technologies, businesses will be able to deploy a Zero Trust model across a suite of solutions. Organisations will benefit from secure and adaptive multi-factor authentication, access management across edge solutions, network security policies, incident response and threat intelligence management.

“Thales has partnered with us to help support customers through their digital transformation journeys, and in collaboration we are well primed to provide a zero trust approach with authentication, SOC security and ZTNA solutions. With these integrations, businesses are able to seamlessly secure access to hybrid and cloud environments, detect suspicious account activity, automatically trigger alerts and enforce stronger access policies in real-time,” said Tana Rosenblatt, VP Technology Partnerships, at Palo Alto Networks.

“The business threat landscape is evolving rapidly, leading to an increase in the scale and complexity of risks being faced by many of our clients. As organisations move their network security to the cloud, it becomes more difficult to implement holistic security controls. We are excited to be able to work with Palo Alto Networks and offer organisations a clear path towards identity-aware Zero Trust security.

By applying and enforcing adaptive and multi-factor authentication at the network edge, and by responding to and stopping untrusted access events in real-time, Thales and Palo Alto Networks ensure organisations can make the move to the cloud successfully and securely,” concluded Francois Lasnier, VP Access Management Products at Thales.

For businesses looking to roll out Zero Trust frameworks within their networks, Thales and Palo Alto Networks security solutions are available to integrate now. To learn more about rolling out Zero Trust frameworks using Thales and Palo Alto Networks security solutions, join our RSA Conference roundtable session that discusses identity centric Zero Trust with Palo Alto Networks by reserving one of the limited seats here .

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.

PLEASE VISIT

Thales Group
Security

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye